In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Cartalax | Synthetic analog Cibinetide (ARA-290) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 6 | 366 | |
| Evidence level | Results from animal studies only | Has results from studies in people | |
| Safety | |||
| Safety results | No safety results | 10 (4 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | None registered | 4 | |
Shared outcomes
From the regulatory data of each peptide.
The sources we use show no clinical development. They show no approval at the FDA, the EMA or elsewhere (as of 13 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Cartalax | Cibinetide (ARA-290) |
|---|---|---|
| Kidney functionKidney and urinary | 33 | 29218 |
| Aging markersSkin and wound |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
33
33 |
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Cibinetide (ARA-290) differs from Erythropoietin (human) at 7 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests Cartalax found in ClinicalTrials.gov.
Top 3 of 4 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Araim Pharmaceuticals, Inc.64 participantsJan 2014 to Feb 2015
Neuropathy of Sarcoidosis
Leiden University Medical Center36 participantsFeb 2012 to Feb 2014
Depression
Claes-Göran Östenson24 participantsOct 2013 to est. Dec 2015
Diabetes Type 2 · Impaired Glucose Tolerance · Impaired Fasting Glucose